Abstract:
The present invention provides for the isolation and characterization of canine interleukin-5 (IL-5) and nucleic acid and amino acid sequences of IL-5. More particularly, recombinant DNA molecules encoding for canine interleukin-5 and conservative variants are provided. In other aspects, the invention provides cells comprising the recombinant vectors, and methods for producing canine IL-5 comprising the steps of inserting a transcription regulatory sequence proximal to the IL-5 gene in a cell comprising that gene, and stimulating production of IL-5 through the regulatory sequence.
Abstract:
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.
Abstract:
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.
Abstract:
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.